NCT03740048View on ClinicalTrials.gov

A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

November 4, 2021

Study Completion Date

November 4, 2021

Conditions
End Stage Renal Failure on Dialysis
Interventions
OTHER

Hemodialysis

Hemodialysis frequency will differ in the first six weeks of hemodialysis therapy between the two treatment arms.

DRUG

Patiromer Oral Product

Participants in the intervention group who develop hyperkalemia, during the first six weeks of receiving hemodialysis twice per week, will be treated with Patiromer.

Trial Locations (1)

27157

Wake Forest Baptist Medical Center, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT03740048 - A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease | Biotech Hunter | Biotech Hunter